Ovid Therapeutics Inc. (OVID) Cash Flow Statement
Ovid Therapeutics Inc. (OVID) generated -$54.8M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$54.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
OVIDOvid Therapeutics Inc.Follow OVID — free
—
Price chart with a free account
- Market cap
- 421.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -51.6 | 118.6 | -55.2 | -45.8 | -56.0 | -38.3 | -54.8 | |
| Capital expenditure | 0.4 | 0.2 | 1.4 | 0.1 | 0.2 | 0.0 | -0.0 | |
| Free cash flow | -52.0 | 118.4 | -56.6 | -45.9 | -56.1 | -38.3 | -54.8 | |
| Stock-based compensation | 7.5 | 5.1 | 6.6 | 7.3 | 6.3 | 4.8 | — |
USD millions · SEC XBRL
Ovid Therapeutics Inc. — questions
- What is Ovid Therapeutics Inc.'s operating cash flow?
- -$54.8M over the twelve months to 2026-06-30.
- How much does Ovid Therapeutics Inc. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Ovid Therapeutics Inc.'s free cash flow?
- -$54.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Ovid Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.